Dose Escalation Study of EC D-3263 HCl in Advanced Solid Tumors
Completed · Phase 1
Conditions studied: Solid Tumors
In brief
This is a Phase 1, dose escalation study evaluating safety and pharmacokinetics of enteric coated D-3263 HCl in subjects with advanced solid tumors
Key facts
- Study ID
- NCT00839631
- Run by
- Dendreon
- People needed
- 23
- Starts
- 2009-03-01
- Expected to finish
- 2012-04-01
- Last updated by the study team
- 2012-05-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- histologically or cytologically confirmed advanced solid tumor malignancy which is either refractory to standard therapy or for which no standard therapy exists
- measurable or evaluable disease
- >= 18 years of age
- ECOG of 0, 1 or 2
- no treatement with chemotherapy, radiotherapy or other systemic therapy (excluding depot LHRH agonist or antagonist for subjects with prostate cancer) for the treatment of his or her tumor with in 28 days prior to receipt of EC D-3263 HCl
You may not qualify if…
- Clinically significant coronary artery disease or conduction system abnormality
- Coagulation disorder
- Active infection requiring the use of systemic antimicrobial medications within seven days prior to receipt of EC D-3263 HCl
- Any major surgery within 28 days prior to receipt of EC D-3263 HCl
Where it is running
- South Texas Accelerated Research Therapeutics (START) — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.